Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Other Accumulated Expenses (2024 - 2025)

Xilio Therapeutics' Other Accumulated Expenses history spans 2 years, with the latest figure at $88000.0 for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses fell 36.23% year-over-year to $88000.0; the TTM value through Sep 2025 reached $88000.0, down 36.23%, while the annual FY2024 figure was $131000.0, N/A changed from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $88000.0 at Xilio Therapeutics, down from $196000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $196000.0 in Q2 2025 and bottomed at $28000.0 in Q1 2024.